Ceryvyn Therapeutics Ltd
CYV.AX
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.24B
Close$
Share Statistics
| Market cap | $4.24 Billion |
|---|---|
| Enterprise Value | $4.43 Billion |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | 190.84% |
|---|---|
| Return on Assets | -675.58% |
| Return on Invested Capital | 123.96% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 29540.11 |
| Enterprise Value to EBIT | -10.68 |
| Enterprise Value to Net Income | -12 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | -1.23 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Opthea Limited
33 employees
CEO: Megan Baldwin Ceryvyn Therapeutics Ltd is a clinical-stage biopharmaceutical company developing therapies for the rare lung disease lymphangioleiomyomatosis (LAM). Its lead program, CYV-101, is a fusion protein designed to neutralize VEGF-C and VEGF-D...